About: In silico vaccine design against Chlamydia trachomatis infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In silico vaccine design against Chlamydia trachomatis infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	In silico vaccine design against Chlamydia trachomatis infection
Creator	Barot, Vandana Shiragannavar, Shilpa Hosakeri, · Madagi, ·
source	Medline; PMC
abstract	Chlamydia trachomatis, a gram-negative bacterium known to infect the genital sites mainly columnar epithelial cells of the cervix, urethra and rectum in women and causes acute epididymitis, urinary tract inflammation and DNA damage to the sperms in men, hence considered to be one of the major sexually transmitted infections. The infection is asymptomatic in many people and remains untreated leading to serious health complications, including pelvic inflammatory disease, ectopic pregnancy and infertility. The current treatment options include antibiotics, but the pathogen has gained resistance against many antibiotics. The present work involves an in silico reverse vaccinology approach for identifying the immunogens as vaccine candidates that can be effective against reinfections and should be capable of inducing long-term protective immunity against Chlamydial infections. This study identifies the putative vaccine candidates that are membrane bound with high antigenicity properties; antigenicity induces the immunogenicity which involves identification of T-cell and B-cell epitopes that induce both humoral and cell-mediated immunity. The epitopes ‘LSWEMELAY’, ‘LSNTEGYRY’, ‘TSDLGQMEY’, ‘FIDLLQAIY’ and ‘FSNNFSDIY’ were predicted as core sequences for class I MHC molecules. The identified epitopes showed promising ability to interact with the human leukocyte antigens (HLA). These epitopes showed maximum population coverage with epitope conservancy above 80%. Molecular docking was performed to test the binding affinities of the identified epitopes with the HLA molecule to study the binding cleft interactions. The vaccine candidate thus identified from this study showed to possess the potential to activate the B- and T-cell immune responses which are more specific and make the body stronger against infections and effective for reinfections. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13721-020-00243-w) contains supplementary material, which is available to authorized users.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.1007/s13721-020-00243-w
bibo:pmid	32537381
has license	no-cc
sha1sum (hex)	ec4875f8d3c6b6bef8238cc3a63a3725adbbec37
schema:url	https://doi.org/10.1007/s13721-020-00243-w
resource representing a document's title	In silico vaccine design against Chlamydia trachomatis infection
has PubMed Central identifier	PMC7283423
has PubMed identifier	32537381
schema:publication	Netw Model Anal Health Inform Bioinform
resource representing a document's body	covid:ec4875f8d3c6b6bef8238cc3a63a3725adbbec37#body_text
is schema:about of	named entity 'epitopes' named entity 'current' named entity 'immune responses' named entity 'epitopes' named entity 'predicted' named entity 'epitope' named entity 'AFFINITIES' named entity 'INCLUDING' named entity 'IMMUNOGENS' named entity 'APPROACH' named entity 'INFECTION' named entity 'ANTIBIOTICS' named entity 'IDENTIFICATION' named entity 'THESE' named entity 'sites' named entity 'potential' named entity 'effective' named entity 'cleft' named entity 'vaccine' named entity 'antigenicity' named entity 'B-cell' named entity 'molecular dynamics' named entity 'infertility' named entity 'web server' named entity 'INF-γ' named entity 'peptide' named entity 'subunit vaccine' named entity 'cell-mediated immunity' named entity 'The' named entity 'B-cell' named entity 'class I MHC' named entity 'The infection' named entity 'interact' named entity 'columnar epithelial cells' named entity 'epitope' named entity 'urethra' named entity 'cervix' named entity 'immunogenicity' named entity 'HLA' named entity 'asymptomatic' named entity 'sperms' named entity 'infection' named entity 'membrane bound' named entity 'antibiotics' named entity 'pelvic inflammatory disease' named entity 'T-cell' named entity 'molecule' named entity 'long-term' named entity 'human leukocyte antigens' named entity 'The' named entity 'gained' named entity 'epitopes' named entity 'Arg' named entity 'amino acid' named entity 'co-stimulatory' named entity 'IFN-gamma' named entity 'binding energy' named entity 'epitopes' named entity 'binding affinities' named entity 'blindness' named entity 'membrane bound' named entity 'bioinformatics' named entity 'peptide' named entity 'CD4 cells' named entity 'Human coronaviruses' named entity 'Amino acid' named entity 'antigen' named entity 'epitopes' named entity 'hydrophilicity' named entity 'allergens' named entity 'PEP' named entity 'protein' named entity 'epitopes' named entity '2.2' named entity 'half-life' named entity 'virus' named entity 'vaccine design' named entity 'peptides'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software